ViroStatics, operational since 2007, is a privately held bio-pharmaceutical company headquartered in Sassari, Italy, with operations at the Science & Technology Park of Porto Conte Ricerche (Alghero, Italy) and Business Development in North America. The company has received $22.5 million in investments to date, and is led by an experienced leadership team and advisors.
The Company’s mission is to discover and develop innovative, first-in class, disease-modifying medicines that address the unmet medical needs in viral infections, cancers and inflammatory diseases.
ViroStatics has developed a core platform from which to explore multiple indications, focused on the discovery of novel molecules directed against key cellular functions. This platform is comprised of highly potent and selective inhibitors of transcription (TRI) targeting the cellular kinase CDK9 (cyclin-dependent kinase 9). This kinase plays an important role in viral replication, cancer and inflammation. Moreover, inhibition of CDK9 activity has been demonstrated to be a potentially viable approach for the therapeutic intervention of these diseases.
ViroStatics has developed a robust pipeline of novel, proprietary, selective CDK9 inhibitors for a number of distinct disease indications. These compounds are highly potent with excellent therapeutic indices and attractive drugability characteristics, with patent protection extending beyond 2030.
HIV Program: Initial Indication
• A novel class of Transcription Inhibitors designed to attack the unexploited, post integration phases of HIV replication through CDK9 inhibition
• Rationale: Elite Controllers, a unique group of HIV-infected indivuals with undetectable virus replication in the absence of antiretroviral therapy, over-express p21 that inhibits CDK9, a cyclin-dependent kinase required for HIV transcription (Chen et al. JCI 2011). ViroStatics’ compounds are designed to mimic this aspect of the Elite Controllers phenotype, trying to pharmacologically induce the phenomenon of “elite control” that otherwise rarely occurs naturally
• HIV Program Timeline: By 2015, an IND-enabling package
ViroStatics is fully funded to progress its HIV clinical candidate to IND submission by 2015.
The Company is looking to explore access to capital markets or establish a strategic alliance for the continued development and commercialization of its portfolio.
Franco Lori, MD PhD (CEO) – email@example.com
James Chafouleas, PhD (CBDO) – firstname.lastname@example.org
Sjlva Petrocchi – email@example.com